PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

  • End date
    Nov 4, 2023
  • participants needed
  • sponsor
Updated on 29 November 2020
Pfizer Call Center
Primary Contact
Macquarie University (1.3 mi away) Contact
+50 other location
breast cancer
her2/neu-positive breast cancer


The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only and gastric were studied in Part 1A only). The study will expand to look at selected doses in patients with HER2 positive and negative breast cancer.

Treatment PF-06804103, PF-06804103 + Palbociclib +Letrozole
Clinical Study IdentifierNCT03284723
Last Modified on29 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Esophagogastric Junction Neoplasm or Breast Cancer or Non-Small Cell Lung Cancer or Gastric Cancer or Stomach Cancer?
Do you have any of these conditions: breast tumor or Gastric Cancer or Stomach Cancer or Non-Small Cell Lung Cancer or Breast Cancer or Esophagogastric Junction Neoplasm or breast tumors ...?
Do you have any of these conditions: breast tumors or tumor of the breast or breast tumor or Esophagogastric Junction Neoplasm or Stomach Cancer or Gastric Cancer or Non-Small Cell Lung C...?
HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which no standard therapy is available (Part 1A only)
HER2 positive and negative breast cancer (Part 2A)
HER2 negative breast cancer (Part 1B & Part 2B)
Performance status of 0 or 1
Adequate bone marrow, kidney and liver function

Exclusion Criteria

Known CNS disease including, but not limited to, metastases
History of exposure to certain cumulative doses of anthracyclines
Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
Active and clinically significant bacterial, fungal, or viral infection
Abnormal cardiac function defined by a LVEF <50% by ECHO or MUGA
Patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer


user name

Annotated by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No made yet